Loading clinical trials...
Loading clinical trials...
The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leuk...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559[email protected]Lead Sponsor
Eli Lilly and Company
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT06299540 · Leukemia, Lymphocytic, Chronic, B-Cell
NCT07200375 · Diffuse Large B-Cell Lymphoma
NCT03223610 · Lymphoma, Non-Hodgkin Lymphoma, and more
NCT03418038 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, and more
Beijing Cancer hospital
Beijing
Sun Yat-sen University Cancer Center
Guangzhou
Harbin Medical University Cancer Hospital
Harbin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions